[Evaluation of a new antiemetic, alizapride, in cancerology (author's transl)].

Authors:
  • DCD Cupissol
    D Cupissol
  • FFF Favier
    F Favier
  • CFC Favier
    C Favier
  • BSB Serrou
    B Serrou

  • 3 June 1982
    • journal article
    • abstracts
Abstract
The antiemetic effect of alizapride was evaluated in 50 patients with advanced cancer undergoing chemotherapy with cis-platinum. Our results suggest that alizapride, in a dose of 800 or 900 mg, significantly alleviates nausea and emesis. In a preliminary study, we had established that, without antiemetic therapy, the same patients all suffered from emesis. On the whole, alizapride was well tolerated ; no major side-effects were recorded.